Genetic polymorphisms of cytochrome P450 2C9 causing reduced phenprocoumon (S)-7-hydroxylation in vitro and in vivo

Xenobiotica

Volumn 34, Issue 9, 2004, Pages 847-859

  Ufer, M ^a,b   Kammerer, B ^b   Kahlich, R ^b   Kirchheiner, J ^c   Yasar, U ^a   Brockmoller J ^d   Rane, A ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c HUMBOLDT UNIVERSITY   (Germany)

^d UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; CYTOCHROME P450 2C9; PHENPROCOUMON;

ADULT; AGED; ALLELE; ALLELISM; ANTICOAGULATION; AREA UNDER THE CURVE; ARTICLE; BIOTRANSFORMATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG HYDROXYLATION; DRUG METABOLISM; ENZYME BINDING; FEMALE; GENE DOSAGE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; MALE; NORMAL HUMAN; RACEMIC MIXTURE; REACTION ANALYSIS; STATISTICAL SIGNIFICANCE; STEREOCHEMISTRY; WILD TYPE;

ALLELES; ANTICOAGULANTS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA, COMPLEMENTARY; GENOTYPE; HUMANS; KINETICS; LIVER; MASS SPECTROMETRY; MICROSOMES, LIVER; MODELS, CHEMICAL; PHENPROCOUMON; POLYMORPHISM, GENETIC; RECOMBINANT PROTEINS; TIME FACTORS;

EID: 9144231294     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/00498250400009197     Document Type: Article

References (45)

1. AITHAL, G. P., DAY, C. P., KESTEVEN, P. J. and DALY, A. K., 1999, Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet, 353, 717-719.
2. AYNACIOGLU, A. S., BROCKMOLLER, J., BAUER, S., SACHSE, C., GUZELBEY, P., ONGEN, Z., NACAK, M. and ROOTS, I., 1999, Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. British Journal of Pharmacology, 48, 409-415.
3. DE BOER-VAN DEN BERG, M., THIJSSEN, H. H. and VERMEER, C., 1986, The in vivo effects of acenocoumarol, phenprocoumon and warfarin on vitamin K epoxide reductase and vitamin K-dependent carboxylase in various tissues of the rat. Biochimica et Biophysica Acta, 884, 150-157.
4. DE VRIES, J. X., 1990, Determination of the plasma protein binding of the coumarin anticoagulants phenprocoumon, and its metabolites, warfarin, and acenocoumarol by ultrafiltration and high-performance liquid chromatography. Journal of Chromatography, 529, 479-485.
5. DIETERLE, W., FAIGLE, J. W., MONTICEL, C., SULC, M. and THEOBALD, W., 1977, Biotransformation and pharmacokinetics of acenocoumarol (Sintrom) in man. European Journal of Clinical Pharmacology, 11, 367-375.
6. GUENGERICH, F. P., 1995, Human cytochrome P450 enzymes. In P. R. Ortiz de Montellano (ed.), Cytochrome P450 - Structure, Mechanism, and Biochemistry (New York: Plenum), pp. 473-536.
7. HAINING, R. L., HUNTER, A. P., VERONESE, M. E., TRAGER, W. F. and RETTIE, A. E., 1996, Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. Archives of Biochemistry and Biophysics, 333, 447-458.
8. HE, M., KORZEKWA, K. R., JONES, J. P., RETTIE, A. E. and TRAGER, W. F., 1999, Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9. Archives of Biochemistry and Biophysics, 372, 16-28.
9. HERMANS, J. J. and THIJSSEN, H. H., 1993, Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. British Journal of Pharmacology, 110, 482-490.
10. HIRSH, J., DALEN, J. E., ANDERSON, D. R., POLLER, L., BUSSEY, H., ANSELL, J., DEYKIN, D. and BRANDT, J. T., 1998, Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest, 114, 445S-469S.
11. HUMMERS-PRADIER, E., HESS, S., ADHAM, I. M., PAPKE, T., PIESKE, B. and KOCHEN, M. M., 2003, Determination of bleeding risk using genetic markers in patients taking phenprocoumon. European Journal of Clinical Pharmacology, 59, 213-219.
12. KAMINSKY, L. S. and ZHANG, Z. Y., 1997, Human P450 metabolism of warfarin. Pharmacology and Therapeutics, 73, 67-74.
13. KAMMERER, B., KAHLICH, R., UFER, M., LAUFER, S. and GLEITER, C. H., 2004, Determination of (R)- and (S)-phenprocoumon in human plasma by enantioselective liquid chromatography/electrospray ionisation tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 18, 458-464.
14. KESSLER, H. H., MUHLBAUER, G., STELZL, E., DAGHOFER, E., SANTNER, B. I. and MARTH, E., 2001, Fully automated nucleic acid extraction: MagNA Pure LC. Clinical Chemistry, 47, 1124-1126.
15. KIRCHHEINER, J., UFER, M., WALTER, E. C., KAMMERER, B., KAHLICH, R., MEISEL, C., SCHWAB, M., GLEITER, C. H., RANE, A., ROOTS, I. and BROCKMOLLER, J., 2004, Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteers. Pharmacogenetics, 14, 19-26.
16. LEE, C. R., GOLDSTEIN, J. A. and PIEPER, J. A., 2002, Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics, 12, 251-263.
17. LEVINE, M. N., RASKOB, G., LANDEFELD, S. and KEARON, C., 2001, Hemorrhagic complications of anticoagulant treatment. Chest, 119, 108S-121S.
18. LEWIS, R. J. and TRAGER, W. F., 1970, Warfarin metabolism in man: identification of metabolites in urine. Journal of Clinical Investigation, 49, 907-913.
19. LOWRY, O. H., ROSEBROUGH, N. J., FARR, A. L. and RANDALL, R. J., 1951, Protein measurements with the folin phenol reagent. Journal of Biological Chemistry, 193, 265-275.
20. OMURA, T. and SATO, R., 1964, The carbon monoxide-binding pigment of liver microsomes - evidence of its hemoprotein nature. Journal of Biological Chemistry, 239, 2370-2378.
21. PETERSEN, D., BARTHELS, M., SCHUMANN, G. and BUTTNER, J., 1993, Concentrations of phenprocoumon in serum and serum water determined by high-performance liquid chromatography in patients on oral anticoagulant therapy. Haemostasis, 23, 83-90.
22. POHL, L. R., HADDOCK, R., GARLAND, W. A. and TRAGER, W. F., 1975, Synthesis and thin-layer chromatographic ultraviolet, and mass spectral properties of the anticoagulant phenprocoumon and its monohydroxylated derivatives. Journal of Medical Chemistry, 18, 513-519.
23. RETTIE, A. E., WIENKERS, L. C., GONZALEZ, F. J., TRAGER, W. F. and KORZEKWA, K. R., 1994, Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics, 4, 39-42.
24. SCORDO, M. G., PENGO, V., SPINA, E., DAHL, M. L., GUSELLA, M. and PADRINI, R., 2002, Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clinical Pharmacology and Therapeutics, 72, 702-710.
25. STUBBINS, M. J., HARRIES, L. W., SMITH, G., TARBIT, M. H. and WOLF, C. R., 1996, Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics, 6, 429-439.
26. SULLIVAN-KLOSE, T. H., GHANAYEM, B. I., BELL, D. A., ZHANG, Z. Y., KAMINSKY, L. S., SHENFIELD, G. M., MINERS, J. O., BIRKETT, D. J. and GOLDSTEIN, J. A., 1996, The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics, 6, 341-349.
27. TAKAHASHI, H. and ECHIZEN, H., 2001, Pharmacogenetics of warfarin elimination and its clinical implications. Clinical Pharmacokinetics, 40, 587-603.
28. TAKAHASHI, H., KASHIMA, T., NOMOTO, S., IWADE, K., TAINAKA, H., SHIMIZU, T., NOMIZO, Y., MURAMOTO, N., KIMURA, S. and ECHIZEN, H., 1998, Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes. Pharmacogenetics, 8, 365-373.
29. TAUBE, J., HALSALL, D. and BAGLIN, T., 2000, Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood, 96, 1816-1819.
30. THIJSSEN, H. H., DRITTIJ, M. J., VERVOORT, L. M. and de VRIES-HANJE, J. C., 2001, Altered pharmacokinetics of R- and S-acenocoumarol in a subject heterozygous for CYP2C9*3. Clinical Pharmacology and Therapeutics, 70, 292-298.
31. THIJSSEN, H. H., FLINOIS, J. P. and BEAUNE, P. H., 2000a, Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes. Drug Metabolism and Disposition, 28, 1284-1290.
32. THIJSSEN, H. H., VERKOOIJEN, I. W. and FRANK, H. L., 2000b, The possession of the CYP2C9*3 allele is associated with low dose requirement of acenocoumarol. Pharmacogenetics, 10, 757-760.
33. TOON, S., HEIMARK, L. D., TRAGER, W. F. and O'REILLY, R. A., 1985, Metabolic fate of phenprocoumon in humans. Journal of Pharmacological Sciences, 74, 1037-1040.
34. TOWBIN, H., STAEHELIN, T. and GORDON, J., 1979, Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proceedings of the National Academy of Sciences, USA, 76, 4350-4354.
35. UFER, M., KAMMERER, B., KIRCHHEINER, J., RANE, A. and SVENSSON, J. O., 2004a, Determination of phenprocoumon, warfarin and their monohydroxylated metabolites in human plasma and urine by high-performance liquid chromatography-mass spectrometry after solid-phase extraction. Journal of Chromatography B, 809, 217-226.
36. UFER, M., SVENSSON, J. O., KRAUSZ, K. W., GELBOIN, H. V., RANE, A. and TYBRING, G., 2004b, Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro. European Journal of Clinical Pharmacology, 60, 173-182.
37. VISSER, L. E., VAN VLIET, M., VAN SCHAIK, R. H., KASBERGEN, A. A., DE SMET, P. A., VULTO, A. G., HOFMAN, A., VAN DUIJN, C. M. and STRICKER, B. H., 2004, The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 and CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Pharmacogenetics, 14, 27-33.
38. VON BAHR, C., GROTH, C. G., JANSSON, H., LUNDGREN, G., LIND, M. and GLAUMANN, H., 1980, Drug metabolism in human liver in vitro: establishment of a human liver bank. Clinical Pharmacology and Therapeutics, 27, 711-725.
39. WIENKERS, L. C., WURDEN, C. J., STORCH, E., KUNZE, K. L., RETTIE, A. E. and TRAGER, W. F., 1996, Formation of (R)-8-hydroxywarfarin in human liver microsomes. A new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19. Drug Metabolism and Disposition, 24, 610-614.
40. YAMAZAKI, H., INOUE, K., CHIBA, K., OZAWA, N., KAWAI, T., SUZUKI, Y., GOLDSTEIN, J. A., GUENGERICH, F. P. and SHIMADA, T., 1998a, Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes. Biochemical Pharmacology, 56, 243-251.
41. YAMAZAKI, H., INOUE, K. and SHIMADA, T., 1998b, Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes. Xenobiotica, 28, 103-115.
42. YASAR, Ü., ELIASSON, E., DAHL, M. L., JOHANSSON, I., INGELMAN-SUNDBERG, M. and SJOQVIST, F., 1999, Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochemical Biophysical Research Communications, 254, 628-631.
43. YASAR, Ü., TYBRING, G., HIDESTRAND, M., OSCARSON, M., INGELMAN-SUNDBERG, M., DAHL, M. L. and ELIASSON, E., 2001, Role of CYP2C9 polymorphism in losartan oxidation. Drug Metabolism and Disposition, 29, 1051-1056.
44. YASUKOCHI, Y. and MASTERS, B. S., 1976, Some properties of a detergent-solubilized NADPH-cytochrome c(cytochrome P-450) reductase purified by biospecific affinity chromatography. Journal of Biological Chemistry, 251, 5337-5344.
45. ZHANG, Z. Y., KERR, J., WEXLER, R. S., LI, H. Y., ROBINSON, A. J., HARLOW, P. P. and KAMINSKY, L. S., 1997, Warfarin analog inhibition of human CYP2C9-catalyzed S-warfarin 7-hydroxylation. Thrombosis Research, 88, 389-398.